Differentiated Autologous PRP Remains Well-Positioned for Attractive Long-Term Growth
HOUSTON, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB: AURX) ("Nuo"), a commercial-stage medical device company focused on developing and marketing regenerative therapies for chronic wound care, announced financial results for the second quarter ended June 30, 2026 and provided an operational and business update.
Second Quarter and First Half 2026 Financial Summary
-- Total revenues of approximately $1.77 million and $3.07 million for the
second quarter 2026 and first half of 2026, respectively, were each up in
excess of 150% versus the comparable 2025 periods
-- Total 2Q product revenues increased 38% sequentially versus 1Q 2026 with
Aurix branded product revenues increasing in excess of 30% sequentially
-- Second quarter net operating loss of approximately $167,000 improved by
approximately $280,000 compared to the first quarter of 2026
-- Amended and restated loan agreement with an interim funding of $675,000
and with $325,000 remaining available under commitments totaling $2
million
Operational and Business Update
-- Market continues to respond positively to absolute and relative
improvement in Medicare related reimbursement for Aurix and a vastly
changed overall reimbursement landscape
-- Proposed Medicare PFS and OPPS reimbursement rules issued in July for
January 1, 2027 effectiveness, if finalized as proposed, would support
stable or increasing Medicare payment amounts for autologous PRP
therapies
"Market dynamics continue to support attractive growth opportunities for the Aurix brand and, by extension, Smith+Nephew's private label offering. We remain two months shy of the one-year anniversary of Smith+Nephew's market entry and the initial availability of their private label brand as another differentiated autologous therapy and are pleased to report that the arrangement continues to perform positively," commented David Jorden, Nuo's Chief Executive and Financial Officer. "We recently confirmed the achievement of a reimbursement fee milestone contained in last year's distribution agreement and anticipate receiving that payment this quarter".
"We amended January's loan agreement in May with additional capital made available via an interim funding and have the company option to increase total borrowings under the agreement on September 30, 2026. The loan remains designed to provide working capital as we invest in growth and move closer to breakeven operations".
About Nuo Therapeutics
Nuo Therapeutics, Inc. is a commercial-stage medical device company focused on developing and marketing regenerative therapies for chronic wound care. Nuo's Aurix System is a biodynamic hematogel that harnesses a patient's innate regenerative abilities for the management of a variety of wounds.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements. These forward-looking statements include but are not limited to statements regarding Nuo's anticipated growth opportunities and market positioning, expectations regarding Medicare reimbursement changes and their impact on demand for Aurix products, future receipt of milestone payments, and movement toward breakeven operations. Forward-looking statements may include statements that are predictive in nature and depend upon or refer to future events or conditions, and may include words such as "believes," "plans," "anticipates," "projects," "estimates," "expects," "intends," "strategy," "future," "opportunity," "may," "will," "should," "could," "potential," or similar expressions. You are cautioned not to unduly rely on forward-looking statements. Forward-looking statements are based on current expectations, assumptions, and information available to Nuo's management and are subject to known and unknown risks, uncertainties and other factors which may cause actual results to differ materially from the forward-looking statements. These risks, uncertainties, and factors are discussed under "Risk Factors" and elsewhere in Nuo's public filings with the U.S. Securities and Exchange Commission from time to time, including Nuo's annual report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. You are advised to carefully consider these various risks, uncertainties, and other factors. Nuo expressly disclaims any intent or obligation to update or revise publicly these forward-looking statements except as required by law.
Contact:
David Jorden
djorden@nuot.com
NUO THERAPEUTICS, INC.
CONSOLIDATED BALANCE SHEETS
(Unaudited)
June 30, December 31,
2026 2025
------------ ------------
ASSETS
Current assets
Cash $ 449,325 $ 548,946
Accounts receivable, net 1,167,571 561,667
Inventory, net 269,518 213,761
Prepaid expenses and other current
assets 107,021 55,509
----------- -----------
Total current assets 1,993,435 1,379,883
Property and equipment, net 571,735 366,315
Operating lease right of use assets 61,120 99,464
----------- -----------
Total assets $ 2,626,290 $ 1,845,662
=========== ===========
LIABILITIES AND STOCKHOLDERS'
DEFICIT
Current liabilities
Accounts payable $ 563,100 $ 436,083
Accrued expenses 619,046 493,792
Deferred revenue 311,765 300,000
Current portion of operating lease
liabilities 60,090 76,410
----------- -----------
Total current liabilities 1,554,001 1,306,285
Deferred revenue -- long term 857,353 975,000
Notes payable 1,436,250 300,000
Note payable -- related party 314,000 200,000
Non-current portion of operating
lease liabilities - 20,936
----------- -----------
Total liabilities 4,161,604 2,802,221
----------- -----------
Commitments and contingencies
Stockholders' deficit
Common stock; $0.0001 par value,
100,000,000 shares authorized,
48,418,524 and 48,179,039 shares
issued and outstanding at June 30,
2026 and December 31, 2025,
respectively 4,842 4,818
Additional paid-in capital 34,128,073 33,810,785
Accumulated deficit (35,668,229) (34,772,162)
----------- -----------
Total stockholders' deficit (1,535,314) (956,559)
----------- -----------
Total liabilities and stockholders'
deficit $ 2,626,290 $ 1,845,662
=========== ===========
NUO THERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
Three Three
Months Months
ended ended
June 30, June 30,
2026 2025
----------- -----------
Revenue
Product sales $ 1,691,045 $ 625,202
Distribution fee revenue 77,941 75,000
---------- ----------
Total revenue 1,768,986 700,202
Costs of sales 598,959 159,350
---------- ----------
Gross profit 1,170,027 540,852
---------- ----------
Operating expenses
Selling, general and administrative 1,336,579 1,192,874
---------- ----------
Total operating expenses 1,336,579 1,192,874
Loss from operations (166,552) (652,022)
---------- ----------
Other income (expense)
Interest income (expense), net (114,066) 1,153
Other income 3,017 1,180
---------- ----------
Total other income (expenses) (111,049) 2,333
Net loss $ (277,601) $ (649,689)
========== ==========
Loss per common share
Basic and diluted $ (0.01) $ (0.01)
Weighted average common shares outstanding
Basic and diluted 48,407,917 46,823,111
NUO THERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
Six Months Six Months
ended ended
June 30, June 30,
2026 2025